Interface Biologics Inc.
Interface Biologics (IBI) develops novel biomedical polymer technologies that enhance the safety and effectiveness of implantable medical devices (a $US 90 billion annual market) by reducing thrombosis, inhibiting infection and providing programmable delivery of pharmaceuticals and biologics. Interface Biologics’ technologies are compatible with a wide range of medical materials, pharmaceuticals and biologics, allowing for widespread adoption across many specialties including cardiology, urology, radiology, oncology and orthopedics. By changing only the surface of the product, the application of IBI polymers does not disrupt the structural integrity of the underlying device.
Interface Biologics has demonstrated capability to apply its patented biomedical polymer technology towards the generation of high value added combination devices both of our own design and of our medical device manufacturer partners.